

B¹
-- This application claims priority from U.S. provisional patent application 60/124,253 filed March 12, 1999 and entitled "Method if isolating CD8+ cells and related hybridoma cells, antibodies and polypeptides."--

✓ At page 5, line 1, paragraph 1 should be amended to read:

B²
-- The hybridoma cell lines designated 37B1 and 8G6 were deposited on December 11, 1997 and March 4, 1999 respectively, pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Virginia 20010-220009 under ATCC Accession Nos. HB-12441 and HB-12657, respectively.--

NE
At page 6, line 26 after AAEGLDTQRFSG kindly insert --(SEQ ID NO:1)---.

At page 8, line 11 after AAEGLDTQRFSG kindly insert --(SEQ ID NO:1)---.

At page 8, line 27 after AAEGLDTQRFSG kindly insert --(SEQ ID NO:1)---.

At page 8, line 30 after AAEGLDTQRFS kindly insert --(SEQ ID NO:2)---.

At page 8, line 34 after NKPAAEGLDTQRFSGKRLG kindly insert --(SEQ ID NO:3)---.

At page 9, lines 8, 15 and 16 after AAEGLDTQRFSG kindly insert --(SEQ ID NO:1)---.

✓ At page 7, line 2 kindly amend the paragraph to read:

-- Such first antibodies include, but are not limited to, the monoclonal antibodies produced by the hybridoma cell lines 37B1 (ATCC Accession No. HB-12441) and 8G6 (ATCC Accession No. HB-12657). Conditions which permit these antibodies to bind to but not activate CD8⁺ cells are well known in the art. These conditions include, for example, a suitable buffer such as Ca²⁺ and Mg²⁺⁺-free Dulbecco's Phosphate Buffer Saline (DPBS) containing 1% Human serum Albumin (HAS) and 0.2% sodium citrate and gentle mixing by "end over end" rotation on a rotator set at 4 rpm.--

B3
✓ Kindly insert the substitute sequence listing provided herewith as pages 15- 16.

Kindly renumber the pages of claims beginning with page 17.

IN THE CLAIMS

✓ Kindly cancel claims 7, 9 and 13.
Kindly amend claim 1 to read:

1. (Twice Amended) A method of isolating human CD8⁺ cells which comprises the steps of
- (a) contacting a sample of isolated peripheral mononuclear blood cells with a first antibody which specifically binds to the sequence AAEGLDTQRFSQ (SEQ ID NO:1) or portion thereof, on CD8 molecules present on the surface of human CD8⁺ cells but does not activate the CD8⁺ cells once bound thereto, under conditions permitting the formation of a first complex between the CD8⁺ cell and first antibody;
 - (b) separating from the sample any first antibody not present in the resulting first complex;
- B5*